UNSPSC 51273021: Phencyclidine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C17H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1JZQ7GDTX, chemically known as piperidine, 1- (1-phenylcyclohexyl)-, hydrochloride but more generally known as phencyclidine hydrochloride, which bears US NIH Compound Identifier 6468. European Medicines Agency schedules Phencyclidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22879.

Most nations, for tariff and trade purposes, schedule phencyclidine hydrochloride under HS 29333300 and SITC 51574. As of Q4 2014, PHENCYCLIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Phencyclidine hydrochloride bears US NLM identifiers UMLS ID C0282301 and NCI Concept Code C75101. SMILES: C1CCC(CC1)C2(CCCCC2)N3CCCCC3.CL.

UNSPSC 51273021 Phencyclidine hydrochloride is a Commodity code that does not reflect the actual scope of state and local procurement activity associated with it. The recent opportunities tagged to this code involve naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products—none of which are phencyclidine hydrochloride or controlled precursors. The code shows a fundamental mismatch between its nominal scope and the work state and local governments are actually buying under it. State and local issuing bodies pursuing pharmaceutical procurement—including county health departments, state health and human services commissions, and cooperative purchasing alliances—are soliciting naloxone distribution, direct-to-manufacturer prescription programs, and generic pharmaceutical supply agreements, not phencyclidine hydrochloride itself.

Recent activity includes Seminole County, Florida issuing IFB 60459723LAS for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the Texas Health and Human Services Commission posting Request for Information HHS0017013 on direct-to-manufacturer prescription capability on April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issuing RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effectiveness. Geographic activity spans Florida, Texas, Minnesota, and Oregon. Because the code's nominal product—phencyclidine hydrochloride—bears no relationship to any of these opportunities, this code presents minimal relevance for pursuing legitimate state and local pharmaceutical procurement work.